

## Position statement on the prescribing of Doxazosin modified release

Following the NHS England guidance 'Items which should not routinely be prescribed in primary care: Guidance for CCGs (version 2, June 2019) the following changes to prescribing have been agreed across Barking and Dagenham, Havering and Redbridge.

**From 17th September 2019**  
**Barking and Dagenham, Havering and Redbridge Clinical Commissioning Groups (BHR CCGs) no longer supports the prescribing of Doxazosin modified release (M/R)**

### Decision

- The decision to stop Doxazosin m/r applies to ALL patients across Barking and Dagenham, Havering and Redbridge. BHR CCGs have agreed NO exceptions to this recommendation

Please note that Doxazosin immediate release remains available.

### This decision was made because:

- There are two oral forms of the medication (immediate release and prolonged-release) and both are taken once daily. Prolonged-release Doxazosin (M/R) is approximately six times the cost of doxazosin immediate release ([Drug Tariff](#)).
- NICE guideline: [NICE CG97 \(last updated June 2015\) Lower urinary tract symptoms in men: management](#) recommends Doxazosin as an option in men with moderate to severe lower urinary tract symptoms. It does not identify benefits of Prolonged-release above immediate release.
- BHR CCGs have a duty to spend taxpayer's money wisely, to make sure they get the best value possible – especially when NHS funding is being severely squeezed and more patients are being seen with more complex health issues than ever before

### Reference:

NHS England and NHS Improvement. Items which should not routinely be prescribed in primary care: Guidance for CCGs. Version 2, June 2019. Publishing approval reference 000608 <https://www.england.nhs.uk/publication/items-which-should-not-be-routinely-prescribed-in-primary-care-guidance-for-ccgs/>